All Updates

All Updates

icon
Filter
FDA approval
Brainomix receives FDA clearance for 'e-Lung' imaging product
Precision Medicine
May 17, 2024
Last week:
Geographic expansion
Partnerships
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Industry news
Partnerships
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Precision Medicine

Precision Medicine

May 17, 2024

Brainomix receives FDA clearance for 'e-Lung' imaging product

FDA approval

  • Brainomix has received FDA clearance for its new lung imaging product, Brainomix 360 e-Lung. This AI-powered software is designed to support the diagnosis and management of lung diseases, particularly idiopathic pulmonary fibrosis (IPF). It marks Brainomix's entry into the lung imaging sector after making a name in the stroke AI imaging field.

  • The software analyzes lung scans using imaging and AI algorithms to identify patterns of fibrosis and other abnormalities. Its key features include AI-infused imaging biomarkers specifically designed for the pulmonary field. 

  • Brainomix claims that the e-Lung could significantly expedite healthcare delivery and improve clinical outcomes for patients with lung disease. By employing AI-powered imaging, the solution could enhance healthcare professionals' ability to make informed diagnostic and treatment decisions, potentially leading to improved patient outcomes.

  • Brainomix is a UK-based biotechnology company specializing in developing AI-powered imaging biomarkers. The company offers several key products within its Brainomix 360 platform, which includes modules such as e-ASPECTS for automated stroke assessment on CT scans, e-CTA for evaluating blood vessel status, e-CTP for assessing brain perfusion, and e-Lung for diagnosis of lung diseases. The company’s entry into the lung imaging space is followed by its Brainomix 360 Stroke platform, commercialized in the US and Europe.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.